Response to thalidomide in multiple myeloma: impact of angiogenic factors.
Thalidomide has antiangiogenic and immunomodulatory effects, mediated by several cytokines such as vascular endothelial growth factor (VEGF), fibroblastic growth factor (FGF-2), hepatocyte growth factor (HGF), interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-alpha). Although extramedullary plasmacytomas (EMP) have a high vascularization, the response of these patients to thalidomide is controversial. Thirty-eight patients with refractory/relapsed MM were treated with thalidomide. Eleven patients had EMP when therapy was initiated. Serum specimens were obtained in patients before treatment was started and at the time of maximum response in responding patients or at thalidomide discontinuation in non-responders. Serum levels of VEGF, HGF and FGF-2 were determined in 18 patients whereas IL-6 and TNF-alpha were measured in 19 patients. Sixteen of the 38 patients (42%) responded to thalidomide. The response rate was significantly higher in patients without EMP (59% vs 0%, p = 0.0006 ). VEGF serum levels were significantly higher in responding patients. In contrast, baseline serum levels of HGF were significantly lower in responders. Neither VEGF nor HGF serum levels showed correlation with the presence of EMP. Baseline TNF-alpha serum levels were significantly lower in responding patients and in those without EMP. The serum levels of FGF-2 and IL-6 did not correlate with response to treatment or presence of EMP.
Rosiñol
Laura
L
Institut Clínic de Malaties Hemato-Oncològiques, Hematology Department, Institut d' Investigacions Biomèdiques Agustí Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Cibeira
M Teresa
MT
Segarra
Marta
M
Cid
Maria C
MC
Filella
Xavier
X
Aymerich
Marta
M
Rozman
María
M
Arenillas
Leonor
L
Esteve
Jordi
J
Bladé
Joan
J
Montserrat
Emili
E
D043925:Angiogenesis Inducing Agents / Q000097:blood*; D020533:Angiogenesis Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D042501:Angiogenic Proteins / Q000097:blood; D016207:Cytokines / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000097:blood / Q000188:drug therapy* / Q000473:pathology; D010954:Plasmacytoma / Q000097:blood / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D012008:Recurrence; D013792:Thalidomide / Q000494:pharmacology*; D016896:Treatment Outcome
D043925:Angiogenesis Inducing Agents; D020533:Angiogenesis Inhibitors; D042501:Angiogenic Proteins; D016207:Cytokines; D013792:Thalidomide